HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTFA guidelines

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association is requesting public comments on two new and one revised Safety Evaluation Guidelines by July 8, CTFA announces. The two new guidelines for genotoxicity and reproductive and developmental toxicity testing describe both in vivo and in vitro models, while the revised guidelines on photoirritation/photoallergy include in vivo, in vitro and clinical test methods, association notes. CTFA Safety Evaluation Guidelines "provide manufacturers with guidance regarding the use of preclinical and clinical safety testing as means to substantiate the safety of both ingredients and finished cosmetic products"...

You may also be interested in...



CTFA guidelines

The Cosmetic, Toiletry and Fragrance Association is requesting comments on a new Safety Evaluation Guideline on in vitro test methods for evaluating skin absorption; comments are due by Sept. 25. The association's guidelines "provide manufacturers with guidance regarding the use of preclinical and clinical safety testing as a means to substantiate the safety of both ingredients and finished cosmetic products." In June, CTFA requested comments on two new guidelines for genotoxicity and reproductive and developmental toxicity testing as well as revised guidelines on photoirritation/photoallergy (1"The Rose Sheet" June 26, 2006, In Brief)...

Expectations Are High For New EMA Boss

Emer Cooke seems set to take over as head of the European Medicines Agency – one of the world's most powerful regulatory bodies – before the end of the year. We report on the reaction of a range of pharmaceutical sector stakeholders to her nomination.

Clif Bar Claims In Google Ads Clipped In Accelerated Review Of Kind Challenge

Clif Bar didn’t convince National Advertising Division a challenge by Kind is too “complex” for the SWIFT forum. NAD attorneys determined Clif didn’t support its claims of sustained energy and “better” performing ability.

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel